Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 441.55B P/E 34.46 EPS this Y 1.10% Ern Qtrly Grth -8.90%
Income 16.38B Forward P/E 16.54 EPS next Y 6.90% 50D Avg Chg 5.00%
Sales 86.58B PEG 2.92 EPS past 5Y 5.76% 200D Avg Chg 3.00%
Dividend 3.00% Price/Book 5.87 EPS next 5Y 5.53% 52W High Chg -6.00%
Recommedations 2.40 Quick Ratio 0.77 Shares Outstanding 2.41B 52W Low Chg 13.00%
Insider Own 0.09% ROA 8.10% Shares Float 2.40B Beta 0.52
Inst Own 72.62% ROE 22.15% Shares Shorted/Prior 23.03M/19.81M Price 169.91
Gross Margin 69.43% Profit Margin 43.91% Avg. Volume 7,935,243 Target Price 172.09
Oper. Margin 29.82% Earnings Date Oct 15 Volume 14,213,937 Change 0.60%
About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson News
12/20/24 Is Johnson & Johnson (JNJ) a Cheap NYSE Stock to Invest in Now?
12/20/24 The 10 biggest medtech stories of 2024
12/19/24 Why Is Johnson & Johnson (JNJ) Among the Best Dividend Stocks to Invest In?
12/18/24 Jim Cramer on Johnson & Johnson (JNJ): How the Pharma Giant is Handling Billion-Dollar Lawsuits and Legal Battles
12/18/24 SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
12/18/24 Tessera gets sickle cell funding; Corvus shares slide on eczema data
12/18/24 The Smartest Dividend Stocks to Buy With $500 Right Now
12/17/24 FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC
12/17/24 Johnson & Johnson (NYSE:JNJ) Has A Pretty Healthy Balance Sheet
12/16/24 Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
12/16/24 Market Chatter: Johnson & Johnson Sues Cigna Units Over Alleged Drug Fund Misuse
12/16/24 EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease
12/16/24 PFA to surpass radiofrequency ablation in 2025: Citi survey
12/13/24 J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds
12/13/24 Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
12/13/24 Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
12/13/24 Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
12/13/24 FDA grants PMA approval to J&J MedTech’s heart pumps for paediatric use
12/12/24 These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over
12/11/24 Johnson & Johnson reinstated with a Neutral at BofA
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Fasolo Peter Exec VP, Chief HR Of.. Exec VP, Chief HR Officer Jul 25 Sell 170.3249 20,000 3,406,498 102,696 07/27/23
Hait William See Remarks See Remarks Jul 26 Sell 172 14,698 2,528,056 87,747 07/27/23
Hait William See Remarks See Remarks Jul 26 Option 90.44 14,698 1,329,287 102,445 07/27/23
Swanson James D. See Remarks See Remarks Mar 06 Sell 154.6600 1,062 164,199 9,215 03/08/23
McEvoy Ashley EVP, WW Chair, MedTe.. EVP, WW Chair, MedTech Nov 30 Option 72.54 73,323 5,318,850 115,136 12/02/22
McEvoy Ashley EVP, WW Chair, MedTe.. EVP, WW Chair, MedTech Nov 30 Sell 175.77 73,323 12,887,984 41,813 12/02/22
Wengel Kathryn E EVP, Chief GSC Offic.. EVP, Chief GSC Officer Nov 09 Option 72.54 16,410 1,190,381 87,721 11/10/22
Wengel Kathryn E EVP, Chief GSC Offic.. EVP, Chief GSC Officer Nov 09 Sell 173.42 16,410 2,845,822 71,311 11/10/22
Mongon Thibaut Exec VP, WW Chair, C.. Exec VP, WW Chair, Consumer Nov 07 Option 108.77 17,043 1,853,767 57,176 11/09/22
Mongon Thibaut Exec VP, WW Chair, C.. Exec VP, WW Chair, Consumer Nov 04 Sell 171.18 35,246 6,033,410 40,133 11/08/22
Mongon Thibaut Exec VP, WW Chair, C.. Exec VP, WW Chair, Consumer Nov 04 Option 130.73 35,246 4,607,710 75,379 11/08/22
Wengel Kathryn E EVP, Chief GSC Offic.. EVP, Chief GSC Officer Jun 10 Option 72.54 40,000 2,901,600 111,311 06/14/22
Wengel Kathryn E EVP, Chief GSC Offic.. EVP, Chief GSC Officer Jun 10 Sell 173 40,000 6,920,000 71,311 06/14/22
Decker Robert J Controller, CAO Controller, CAO May 26 Option 72.54 8,462 613,833 23,935 05/31/22
Decker Robert J Controller, CAO Controller, CAO May 26 Sell 180 8,462 1,523,160 15,473 05/31/22
Hait William See Remarks See Remarks Apr 21 Option 90.44 29,699 2,685,978 109,935 04/25/22
Hait William See Remarks See Remarks Apr 21 Sell 183.58 29,699 5,452,142 80,236 04/25/22
Gorsky Alex Director Director Jan 14 Option 65.37 231,951 15,162,637 695,601 01/19/22
Duato Joaquin CEO CEO Jan 14 Option 65.37 84,423 5,518,732 280,475 01/19/22
Sneed Michael E EVP, Global Corp Aff.. EVP, Global Corp Aff & COO Dec 10 Option 62.2 54,662 3,399,976 110,741 12/10/20
Sneed Michael E EVP, Global Corp Aff.. EVP, Global Corp Aff & COO Dec 10 Sell 152.93 54,662 8,359,460 56,079 12/10/20